RESEARCH · TIRZEPATIDE · WITHDRAWAL & MAINTENANCE
What Happens When Tirzepatide Stops? SURMOUNT-4, SURMOUNT-MAINTAIN and the Weight-Regain Evidence
PurixLab’s Tirzepatide 10mg is a research vial of the dual GIP/GLP-1 receptor agonist. Our earlier articles cover the SURPASS and SURMOUNT programme and body composition and liver fat, and a separate piece compares single, dual and triple incretin agonists. This article looks at a question those trials leave open: what randomised withdrawal and maintenance trials show happens to body weight and cardiometabolic markers when tirzepatide is stopped, continued or stepped down. These are published clinical-trial findings about the drug under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
The randomised withdrawal design
SURMOUNT-4 enrolled 783 adults with obesity or overweight, excluding diabetes, into a 36-week open-label tirzepatide lead-in, then randomised 670 participants 1:1 to continue tirzepatide or switch to placebo for 52 weeks [1]. Participants lost a mean 20.9% of body weight during the lead-in. From week 36 to week 88, weight changed by −5.5% with continued tirzepatide versus +14.0% with placebo, a difference of −19.4% [1]. At week 88, 89.5% of the continued group had maintained at least 80% of their lead-in weight loss, versus 16.6% of the placebo group, and the overall reduction from week 0 to 88 was 25.3% versus 9.9% [1]. The authors concluded that withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented the initial reduction [1].
Regain and cardiometabolic markers
A post hoc analysis followed 308 placebo-switched participants who had lost 10% or more by week 36. Most regained 25% or more of their lost weight within a year, and the mean rise in waist circumference grew from 0.8 cm in those regaining less than 25% to 14.7 cm in those regaining 75% or more, with systolic blood pressure, non-HDL cholesterol and HbA1c also rising more in the groups with greater regain [2]. In the group regaining less than 25%, waist circumference, non-HDL cholesterol and fasting insulin at week 88 were not significantly different from week 36 [2]. Health-related quality-of-life scores improved during the lead-in, were maintained with continued treatment, and worsened with greater regain after the switch to placebo [3].
Semaglutide shows the same pattern
The withdrawal finding is not unique to dual agonism. In STEP 4, after a 20-week semaglutide run-in with a mean 10.6% weight loss, 803 participants were randomised 2:1; from week 20 to week 68, body weight changed by −7.9% with continued semaglutide versus +6.9% after switching to placebo [4]. In the STEP 1 off-treatment extension of 327 participants, those who stopped semaglutide regained 11.6 percentage points of lost weight by week 120, about two-thirds of their prior loss, and most cardiometabolic improvements reverted towards baseline [5].
Continue, stop or step down?
SURMOUNT-MAINTAIN tested a third option. After a 60-week open-label weight-loss period at the maximum tolerated dose, 378 participants were randomised 3:3:2 to continue, step down to a lower maintenance dose, or switch to placebo for 52 weeks, with rescue tirzepatide allowed from week 84 if regain exceeded 50% [6]. The model-based change in body weight from baseline to week 112 was −21.9% with continued treatment, −16.6% with the reduced dose and −9.9% with placebo, and rescue therapy was received by 8%, 25% and 67% of participants in the three arms [6]. The authors suggest that stepping down might be an alternative to discontinuation, although individual responses might vary [6].
Long continuous treatment gives context. In the 3-year SURMOUNT-1 analysis of participants with obesity and prediabetes, weight change at 176 weeks ranged from −12.3% to −19.7% across tirzepatide groups versus −1.3% with placebo; after a 17-week off-treatment period, 2.4% of tirzepatide-treated and 13.7% of placebo participants had type 2 diabetes [7]. In a post hoc analysis of adherent participants with prediabetes from that trial, 70% regained less than 5% from their weight nadir to week 176 [8], and most SURMOUNT-1 participants had reached a weight plateau by week 72 [9].
Pooled analyses disagree on drug differences
A meta-analysis of six studies and 8,993 patients found a mean difference of 17.90% in weight between discontinuation and continued-treatment groups, and its subgroup analysis reported a larger rebound after tirzepatide than semaglutide [10]. A Bayesian re-analysis of six studies and 1776 participants estimated regain of 1.04 kg per month after stopping, with 50% of lost weight projected to return by 7.50 months; tirzepatide regained numerically faster in unadjusted analyses, but no clear independent drug-specific difference remained after adjustment, and estimates beyond 52 weeks were model-based extrapolations [11]. Greater initial weight loss showed the strongest directional association with faster regain, although its credible interval included zero [11], so a drug producing larger losses can look worse on regain without differing in mechanism.
Proposed mechanisms include restoration of appetite once pharmacological GLP-1 signalling stops, compensatory increases in ghrelin and changes in incretin balance, with much of the regain occurring early after cessation [12]. Whether structured tapering allows successful discontinuation has not been tested prospectively [12].
What remains open
- Tapering. Whether structured tapering can replace abrupt withdrawal remains unknown and needs prospective evaluation [12].
- Who maintains without medication. Maintenance requirements vary substantially between individuals, and early warning signs of relapse still need prospective validation [13].
- Duration. Controlled off-treatment follow-up is at most about a year; longer trajectories are modelled rather than observed [11,5].
- Hard outcomes. Withdrawal trials report weight and risk markers, not cardiovascular events [1,2].
Tirzepatide 10mg at PurixLab
Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PubMed 38078870 · PMC10714284 · doi:10.1001/jama.2023.24945
- Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157-167. PubMed 41284285 · PMC12645400 · doi:10.1001/jamainternmed.2025.6112
- Gibble TH, Cao D, Murphy M, et al. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4. Obesity (Silver Spring). 2025;33(11):2076-2092. PubMed 40903801 · PMC12559773 · doi:10.1002/oby.70011
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PubMed 33755728 · PMC7988425 · doi:10.1001/jama.2021.3224
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470 · PMC9542252 · doi:10.1111/dom.14725
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. PubMed 42119587 · doi:10.1016/S0140-6736(26)00656-2
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. PubMed 39536238 · doi:10.1056/NEJMoa2410819
- Aronne LJ, Vincent RP, Klein KR, et al. Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes. Obes Pillars. 2026;20:100333. PubMed 42831032 · PMC13634289 · doi:10.1016/j.obpill.2026.100333
- Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734. PubMed 39800653 · PMC12096058 · doi:10.1111/cob.12734
- Qi H, Gao Q, Chen H, et al. Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis. PeerJ. 2026;14:e21713. PubMed 42729958 · PMC13564392 · doi:10.7717/peerj.21713
- Kow CS, Thiruchelvam K, Ramachandram DS, et al. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis. Endocrinol Diabetes Metab. 2026;9(5):e70325. PubMed 42673571 · PMC13529306 · doi:10.1002/edm2.70325
- Damhof MA, van Bruggen FH, van Roon EN. Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies. Diabetes Obes Metab. 2026;28(10):8769-8776. PubMed 42396734 · PMC13538768 · doi:10.1111/dom.71075
- van Bruggen FH, Damhof MA, van Roon EN. Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm. Obes Pillars. 2026;20:100327. PubMed 42733607 · PMC13571586 · doi:10.1016/j.obpill.2026.100327